Regentis Biomaterials (NYSE American: RGNT) announced that the U.S. Patent and Trademark Office has issued the company a new patent titled “Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof,” covering a liquid, ready-to-use formulation of its lead product, GelrinC(R), as well as improved production processes that eliminate the use of organic solvents. The patent focuses on GelrinC’s liquid formulation, which is designed to simplify surgical procedures and improve patient experience by conforming precisely to cartilage wounds before being cured with UV light to form a temporary elastomeric implant. Regentis said the patent provides protection for GelrinC through 2038 and comes as the company has surpassed 50% enrollment in its pivotal U.S. Food and Drug Administration clinical trial for knee cartilage repair, according to Executive Chairman Dr. Ehud Geller.
To view the full press release, visit https://ibn.fm/bB9os
About Regentis Biomaterials
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
For more information, visit, https://www.regentis.co.il/
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
